Skip to content
DataLookout
Menu

DESTINY-Lung06NCT06899126

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 246 to 247
  2. Minor Trial sites expanded: 242 → 246 locations
  3. Notable Eligibility criteria expanded, about 14 words
    • Trial sites expanded: 237 → 242 locations
    • Collaborators: details revised at 1 of 1 entry
    • Publications: details revised at 1 of 1 entry
  4. Minor Trial sites expanded: 160 → 237 locationsv7
  5. Notable Eligibility criteria expanded, about 55 wordsv6 Show 5 more changesShow less
    • Primary completion pushed from Mar 5, 2030 to Apr 24, 2030
    • Trial sites expanded: 100 → 160 locations
    • Study completion pushed from Jul 5, 2032 to Nov 24, 2032
    • Interventions: Chemotherapy (Drug), Pemetrexed (Drug), Trastuzumab Deruxtecan (Drug), pembrolizumab (Drug) to Pemetrexed (Drug), Platinum Chemotherapy (Drug), Trastuzumab Deruxtecan (Drug), pembrolizumab (Drug)
    • Secondary endpoints: details revised at 1 of 1 entry
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study sites: 74 to 100v5
  2. Minor Study sites: 26 to 74
    • Start date changed from estimate of Oct 7, 2025 to Oct 24, 2025
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 7, 2025 to Oct 7, 2025
    • Study sites: 0 to 26
    v3
  4. Minor Study title shortened, about 5 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression Free Survival by Blinded Independent Central Review
Timeframe: From date of randomization to the date of radiographic disease progression or death due to any cause, up to approximately 54 months

Secondary (1)

Overall Survival

Arms and interventions

Arm A: T-DXd + PembrolizumabExperimental

Participants will receive T-DXd plus pembrolizumab

Arm B: Pemetrexed + Platinum Chemotherapy + PembrolizumabActive comparator

Participants will receive Pemetrexed plus platinum chemotherapy (cisplatin or carboplatin) plus pembrolizumab

Drugs: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy

Sites

247 sites in 24 countries

China 31, United States 26, Japan 22, Spain 20, Brazil 17, France 17, Argentina 13, Italy 12, Greece 10, Romania 9, South Korea 9, Taiwan 9, Chile 6, India 6, Thailand 6, Turkey (Türkiye) 6, Belgium 5, Germany 5, Hong Kong 4, Malaysia 4, Portugal 4, United Kingdom 4, Mexico 1, Poland 1